MONISTAT 1 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT 1 COMBINATION PACK (MONISTAT 1 COMBINATION PACK).
Miconazole inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death. Miconazole also has direct anti-inflammatory and antibacterial properties.
| Metabolism | Miconazole is primarily metabolized in the liver via oxidative pathways, likely involving cytochrome P450 enzymes, with minor metabolism by reductases. The major metabolites are inactive and excreted in urine and feces. |
| Excretion | Fecal: Approximately 90% of absorbed dose; Renal: <2% as unchanged drug; Biliary: Minor, less than 10%. |
| Half-life | Terminal elimination half-life: 24-30 hours (range 20-50 hours). Clinical context: Once-daily dosing may be considered for some indications, but prolonged half-life supports weekly or twice-weekly regimens for systemic infections. |
| Protein binding | Approximately 90% bound to plasma proteins (mainly albumin); limited binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd: 0.12-0.15 L/kg (12-15 L in 70 kg adult). Clinical meaning: Low Vd indicates limited tissue distribution; primarily confined to plasma and interstitial fluid. |
| Bioavailability | Intravaginal: Systemic absorption <1% after single dose; Oral: 40-50% (females) and 30-40% (males); Rectal: Not established for systemic use. |
| Onset of Action | Intravaginal: Local antifungal effect within 24 hours; Systemic: Not applicable for local use; oral formulation (if taken) requires 2-4 hours for detectable plasma levels. |
| Duration of Action | Intravaginal: Single dose provides therapeutic concentrations for up to 72 hours; Clinical note: Complete eradication of Candida may require longer treatment, typically 1-7 days. |
| Molecular Weight | 416.13 |
Miconazole nitrate 1200 mg vaginal suppository inserted intravaginally once at bedtime; plus external miconazole nitrate 2% cream applied to affected area twice daily for up to 7 days.
| Dosage form | CREAM, INSERT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients less than 12 years of age. |
| Geriatric use | No specific dose adjustment required; use as directed for adults. |
| 1st trimester | Topical miconazole is considered safe; systemic absorption is minimal. Avoid intravaginal use in first trimester unless clearly needed. |
| 2nd trimester | Topical and intravaginal use is generally considered safe; minimal systemic absorption. |
| 3rd trimester | Topical and intravaginal use is safe; no known risk of premature labor or fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT 1 COMBINATION PACK (MONISTAT 1 COMBINATION PACK).
| Placental transfer | Minimal; less than 1.4% of maternal dose crosses placenta based on studies with intravenous miconazole. Topical/intravaginal use yields negligible systemic levels. |
| Breastfeeding | Topical or intravaginal miconazole is poorly absorbed systemically; it is considered compatible with breastfeeding. Avoid application to breast area to prevent infant ingestion. |
■ FDA Black Box Warning
No FDA black box warnings.
| Serious Effects |
Hypersensitivity to miconazole or any componentKnown allergy to other azole antifungals (cross-reactivity)
| Precautions | For vaginal use only; do not use orally or ophthalmically., If symptoms persist or recur within 2 months, seek medical evaluation., May cause local irritation, burning, or allergic reactions., Use during pregnancy only if clearly needed (Category C)., Avoid use with diaphragms or condoms as product may damage latex. |
| Food/Dietary | No significant food interactions. Alcohol consumption does not affect therapy but may exacerbate vulvovaginal irritation in some individuals. |
Loading safety data…
| Lactation Rating | L2 - Safer |
| Teratogenic Risk | Miconazole is a Pregnancy Category C drug. Limited human data; no teratogenic effects have been reported in animal studies at clinically relevant doses. Risk cannot be ruled out, and use is generally avoided in the first trimester unless clearly needed. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required with single-dose vaginal miconazole. Standard obstetric care should continue. |
| Fertility Effects | There are no known adverse effects on fertility from vaginal miconazole. Animal studies have not shown impairment of fertility. |
| Clinical Pearls |
| MONISTAT 1 COMBINATION PACK contains miconazole nitrate (1200 mg vaginal suppository) and external cream (2% miconazole nitrate). For uncomplicated vulvovaginal candidiasis in non-pregnant women. Consider alternative regimens in pregnancy or recurrent infections. Advise patients to complete full course even if symptoms improve. May weaken latex condoms and diaphragms; avoid concurrent use during treatment and for 3 days after. Caution if allergic to other azole antifungals. |
| Patient Advice | Insert one suppository into the vagina at bedtime for one night only. · Apply a thin layer of external cream to the affected area twice daily for up to 7 days for itching and irritation. · Do not use tampons, douches, or spermicides during treatment. · Avoid sexual intercourse during treatment to prevent reinfection and condom damage. · Finish the full regimen even if symptoms resolve early. · Contact your provider if symptoms persist beyond 3 days or if fever, abdominal pain, or foul-smelling discharge occurs. · If pregnant or breastfeeding, consult a healthcare provider before use. |